id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5966-0001,FDA,FDA-2017-D-5966,"Breakthrough Devices Program; Draft Guidance for Industry and Food and
Drug Administration Staff; Availability",Notice,Notice of Availability,2017-10-25T04:00:00Z,2017,10,2017-10-25T04:00:00Z,2017-12-27T04:59:59Z,2017-12-27T14:00:31Z,2017-23195,0,0,0900006482c023b3
FDA-2017-D-5966-0002,FDA,FDA-2017-D-5966,Breakthrough Devices Program Draft Guidance for Industry and Food and Drug Administration Staff,Other,Guidance,2017-10-25T04:00:00Z,2017,10,2017-10-25T04:00:00Z,2017-12-27T04:59:59Z,2024-11-07T01:10:18Z,,1,0,0900006482c034ec